ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Sosei Group Corp.

Business Summary

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company engages in the research, development and sales of medicines; management of regenerative medical funds; investment in bio venture companies related to regenerative medicines; overseas development by licensing; promotions of commercialization; structural analysis of GPCR; initial lead compound creation; candidate search by proprietary StaR (Stabilised Receptor) technology; as well as structural base of new drugs using GPCR related basic technology drug discovery and screening and promotions of antibody drug research and development. The company was founded by Shinichi Tamura and Takaya Nakamura on June 22, 1990 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2019 JPYUSD
Revenue9,726M89.22M
Gross Profit7,809M71.63M
Operating income969M8.88M
Income before tax534M4.89M
Net income1,432M13.13M
EBITDA2,458M22.54M
Diluted EPS18.480.16
Dividends Per Share00
Total Assets56,680M521.55M
Total liabilities11,602M106.75M
Total equity45,075M414.76M
Operating cash flow3,441M31.56M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Dec 2018Dec 2019
Revenue 3,671M 8,151M 18,901M 3,829.32M 9,726M
Gross Profit 3,505M 7,222M 17,978M 2,011.99M 7,809M
Operating income 1,033M 926M 12,128M -7,401.31M 969M
Income before tax 1,301M -3,297M 12,483M -9,635.30M 534M
Net income 516M -1,432M 9,310M -7,947.31M 1,432M
EBITDA 1,131M 1,851M 13,051M -6,030.65M 2,458M
Diluted EPS 9.28 -23.39 137.30 -104.22 18.48
Dividends Per Share 0 0 0 0 0
Total Assets 47,833M 47,354M 48,087M 58,987M 56,680M
Total liabilities 32,991M 24,085M 19,726M 17,407M 11,602M
Total equity 14,601M 23,143M 28,355M 41,577M 45,075M
Operating cash flow 92M 4,471M 12,856M -3,995M 3,441M
 Mar 2015Mar 2016Mar 2017Dec 2018Dec 2019
Revenue 33.41M 67.87M 174.54M 34.67M 89.22M
Gross Profit 31.90M 60.14M 166.02M 18.21M 71.63M
Operating income 9.40M 7.71M 111.99M -67.01M 8.88M
Income before tax 11.84M -27.45M 115.27M -87.24M 4.89M
Net income 4.69M -11.92M 85.97M -71.95M 13.13M
EBITDA 10.29M 15.41M 120.52M -54.60M 22.54M
Diluted EPS 0.08 -0.19 1.26 -0.94 0.16
Dividends Per Share 0 0 0 0 0
Total Assets 398.85M 421.31M 431.54M 537.63M 521.55M
Total liabilities 275.09M 214.28M 177.02M 158.65M 106.75M
Total equity 121.75M 205.90M 254.46M 378.95M 414.76M
Operating cash flow 0.83M 37.23M 118.72M -36.17M 31.56M

Valuation Measures

Dec 2019
PER116.16
ROA2.47%
ROE3.30%
Operating margin9.96%
Profit margin14.72%

Key executives

  • Executive Chairman, President & CEO: Shinichi Tamura
  • Chief Financial Officer & Executive Vice President: Chris Cargill
  • Chief Medical Officer & Executive Vice President: Tim Tasker
  • Group Chief Compliance Officer & Executive VP: Kazuhiko Yoshizumi

Shareholders

  • GOMI DAISUKE (8.0%)
  • Capital International KK (6.6%)
  • Taiyo Pacific Partners LP (4.4%)
  • Taiyo Fund Management LLC (4.1%)
  • Pfizer Inc. (2.3%)
  • Capital Research & Management Co. (World Investors) (2.3%)
  • TAMURA SHINICHI /SOSEI GROUP/ (1.4%)
  • BlackRock Fund Advisors (0.9%)
  • Asset Management One Co., Ltd. (0.7%)
  • Matthews International Capital Management LLC (0.7%)

Contact Details

  • Website:http://sosei.com
  • Address: PMO Hanzomon, 11/F, 2-1 Koji-machi, Tokyo, 102-0083, Japan
  • Phone: +81.3.5210.3290

Related Companies

  • Sosei Group Restricted Stock Compensation Plan
  • Sosei CVC Ltd.
  • EPLUS Co. Ltd.
  • Heptares Therapeutics Ltd.
  • Sosei Co. Ltd.

Competitors

    Last Updated on 25 Sep, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends July 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media